Impressive Lineup of Drugs in Pipeline to Boost Growth Prospects of Global Nonalcoholic Steatohepatitis Market

Nonalcoholic Steatohepatitis (NASH) refers to a liver syndrome found in non-alcoholic patients that damages the liver, rendering it like the liver in alcoholic hepatitis. NASH results from the accumulation of fat in the liver, along with inflammation. Symptoms are not shown in early stages and the condition could lead to cirrhosis, causing permanent liver damage. People suffering from conditions such as glucose intolerance, obesity, and dyslipidemia run a high risk of causing nonalcoholic steatohepatitis (NASH). As most NASH patients are asymptomatic, biopsy is most often required to confirm the diagnosis.

In a recent report, Transparency Market Research (TMR) estimates that the global market for nonalcoholic steatohepatitis will tread along a healthy growth path in the next few years. A number of factors are working in the favor of the market and the rising pool of patients is compelling biotech and pharmaceutical companies to invest in research and development of effective diagnosis and treatment methods for the condition. The market is witnessing an encouraging rise in the number of drugs available to treat the conditions and diagnosis is becoming more accurate.

In its report, TMR states that the global NASH market will exhibit a 10.7% CAGR from 2015 and 2025, rising to an opportunity of US$20.27 bn by 2025.

In this blog post, TMR analysts highlight some of the key trends and opportunities in the global NASH market:

Q. What factors will contribute majorly to the growth of the market in the near future?

A. The NASH market is presently at a nascent stage of development as there are not many U.S. FDA-approved drugs for the disease currently in the global marketplace. However, the market is expected to grow steadily over the coming years as a number of potential drug candidates for NASH are currently in the pipeline at Phase II and III.

The NASH market will also benefit from the fact that healthcare authorities are becoming increasingly concerned about mitigating the larger impact of NASH on the population as well as the socio-economic impact of the disease. This concern stems from the high risk of NASH patients’ condition progressing into cirrhosis. As per information published by the American Liver Foundation, these patients also stand a high risk of developing HCC or hepatocellular cancer. With this becoming a concern, more efforts are expected to be deployed for treating the disease in the near future.

Q. How are biotech and pharma companies responding to opportunities in the global NASH market?

A. The diagnosis and treatment of NASH presents a sizeable opportunity for companies in the pharmaceutical and biotech sector. Factors such as the vast rise in the number of non-alcoholic fatty liver disease (NAFLD) cases (which could lead to NASH), increasing incidence of obesity, and changes in lifestyles of the global population are all eventually projected to act as growth drivers for the global NASH market. This gives companies an opportunity to explore new avenues for growth in the global nonalcoholic steatohepatitis market. 

In the long run, the growth of the NASH market will also be driven due to the fact that NASH is associated with morbid conditions such as insulin resistance and obesity. This indicates a massive unmet demand for drugs and therapeutic treatments for NASH, creating new revenue-generation areas for companies in the market. There is immense scope for novel therapies and formulations to be launched in the global nonalcoholic steatohepatitis market. Thus, innovation will remain the cornerstone of growth for companies vying for a higher share of revenue in the global NASH market.


Post a Comment

Note: only a member of this blog may post a comment.

Latest Post

Market Research Reports